It is not too late to achieve global covid-19 vaccine equity
Open accessAbstract
Gavin Yamey and colleagues say that a new, urgent push for global vaccine equity could help avert suffering and deaths, protect economies, and prevent new virus variants
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Estimates based on official reported COVID-19 deaths represent the lower bound of deaths averted at the global level due to the considerable levels of under-reporting of COVID-19 mortality documented worldwide.
“Importantly, these estimates based on official reported COVID-19 deaths represent the lower bound of deaths averted at the global level due to the considerable levels of under-reporting of COVID-19 mortality documented worldwide.23”
From Global impact of the first year of COVID-19 vaccination: a mathematical modelling study (2022) · cites this paper as [23]
In “Renewed case for vaccine equity” (page not provided), the paper says that under-reporting affects reported COVID-19 mortality and that excess-mortality estimates suggest a higher share of deaths in low- and middle-income countries. It also reports estimates of deaths that further vaccination could avert in those countries. It does not say that estimates based on officially reported deaths are a lower bound for deaths averted globally. (LLM, conf=0.83)
Experimental — accuracy not yet measuredUnder-ascertainment of COVID-19 mortality is a known issue that has hindered understanding of the pandemic.
“Under-ascertainment of COVID-19 mortality is a known issue that has hindered our understanding of the pandemic.23”
From Global impact of the first year of COVID-19 vaccination: a mathematical modelling study (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates
Sallam, M. (2021) · Vaccines · doi:10.3390/vaccines9020160 · Cited by 2,128 · see citing works
Flagged first, then by citations
Research works printed but not linked: 18
- [3]Sheel M McEwen S Davies SE. Brand inequity in access to COVID-19 vaccines. Lancet Reg Health West Pac 2022; 18: 100366. 10.1016/j.lanwpc.2021.100366 35005669 PMC8720145 · DOI
- [5]Wouters OJ Shadlen KC Salcher-Konrad M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 2021; 397: 1023- 34. 10.1016/S0140-6736(21)00306-8 33587887 PMC7906643 · DOI
- [7]Usher AD. A beautiful idea: how COVAX has fallen short. Lancet 2021; 397: 2322- 5. 10.1016/S0140-6736(21)01367-2 34147145 PMC8494620 · DOI
- [8]Yamey G. Rich countries should tithe their vaccines. Nature 2021; 590: 529- 529. 10.1038/d41586-021-00470-9 33627806 · DOI · Paper page
- [14]Sung M Huang Y Duan Y Liu F Jin Y Zheng Z. Pharmaceutical industry’s engagement in the global equitable distribution of covid-19 vaccines: corporate social responsibility of EUL vaccine developers. Vaccines (Basel) 2021; 9: 1183. 10.3390/vaccines9101183 34696293 PMC8539183 · DOI
- [15]Phelan AL Eccleston-Turner M Rourke M Maleche A Wang C. Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access. Lancet 2020; 396: 800- 2. 10.1016/S0140-6736(20)31873-0 32910908 PMC7832682 · DOI
- [17]Mutombo PN Fallah MP Munodawafa D. COVID-19 vaccine hesitancy in Africa: a call to action. Lancet Glob Health 2022; 10: e320- 1. 10.1016/S2214-109X(21)00563-5 34942117 PMC8687664 · DOI
- [18]Cascini F Pantovic A Al-Ajlouni Y Failla G Ricciardi W. Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review. EclinicalMedicine 2021; 40: 101113. 10.1016/j.eclinm.2021.101113 34490416 PMC8411034 · DOI
- [19]Mallapaty S. Researchers fear growing COVID vaccine hesitancy in developing nations. Nature 2022; 601: 174- 5. 10.1038/d41586-021-03830-7 34949861 · DOI
- [20]Bozio CH. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19–like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity—Nine States, January–September 2021. Centers for Disease Control and Prevention 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7044e1.htm PMC8568091 34735425
- [21]Cavanaugh AM. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021. Centers for Disease Control and Prevention. 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm PMC8360277 34383732
- [22]Assis R, Jain A, Nakajima R, et al. Distinct SARS-CoV-2 antibody responses elicited by natural infection and mRNA vaccination. bioRvix 2021:2021.04.15.440089. [Preprint] 10.1101/2021.04.15.440089. PMC8568980 34737318 · DOI
- [24]Röltgen K, Nielsen SCA, Silva O, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 2022 Jan 25. https://www.sciencedirect.com/science/article/pii/S0092867422000769 PMC8786601 35148837
- [26]Mao W Ogbuoji O Watkins D. Achieving global mortality reduction targets and universal health coverage: The impact of COVID-19. PLoS Med 2021;18:e1003675. 10.1371/journal.pmed.1003675 34166391 PMC8270396 · DOI · Paper page
- [27]Savinkina A Bilinski A Fitzpatrick MC. Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 omicron variant era [Preprint]. medRixiv 2022. https://www.medrxiv.org/content/10.1101/2022.02.08.22270465v1 10.1101/2022.02.08.22270465 PMC9471205 36100306 · DOI
- [33]Tseng HF Ackerson BK Luo Y. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. [Preprint]. medRxiv 2022. p. 2022.01.07.22268919. https://www.medrxiv.org/content/10.1101/2022.01.07.22268919v3 PMC9117141 35189624 · DOI
- [35]Chhibber A, Kharat A, Duong K, et al. Strategies to minimize inequity in COVID-19 vaccine access in the US: Implications for future vaccine rollouts. Lancet Regional Health–Americas 2022 Mar 1. https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(21)00134-4/fulltext PMC8652338 34901919
- [36]Saelee R. Disparities in COVID-19 vaccination coverage between urban and rural counties-United States, December 14, 2020-January 31, 2022. Centers for Disease Control and Prevention. 2022. https://www.cdc.gov/mmwr/volumes/71/wr/mm7109a2.htm PMC8893338 35239636
Cited by
Sorted by citations
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study
Watson, O. J., Barnsley, G., Toor, J., Hogan, A. B., Winskill, P., & Ghani, A. C. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00320-6 · Cited by 1,769 · see citing works
Global health 2050: the path to halving premature death by mid-century
Jamison, D. T., Summers, L. H., Chang, A. Y., Karlsson, O., Mao, W., Norheim, O. F., Ogbuoji, O., Schäferhoff, M., Watkins, D., Adeyi, O., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01439-9 · Cited by 125 · see citing works
Self-citationAdvancing mRNA technologies for therapies and vaccines: An African context
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018961 · Cited by 25 · see citing works
- Authors
- Yamey, G., Garcia, P., Hassan, F., Mao, W., McDade, K. K., Pai, M., Saha, S., Schellekens, P., Taylor, A., & Udayakumar, K.
- Affiliations
- Duke University (US)
- Universidad Peruana Cayetano Heredia (PE)
- McGill University (CA)
- Child Health Research Foundation (BD)
- World Bank Group (US)
- Corresponding author
- Yamey, Gavin
- ORCID
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2022-03-24
- Volume
- 376
- Pages
- e070650
- ISSN
- 1756-1833 (ISSN-L)
- PMC
- PMC8943596
- OpenAlex
- W4220883857
- Cited by
- 114
- References
- 1
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 28 · 2023: 33 · 2022: 36
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-03-28)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- BMJ (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Legal, Health, Environmental and COVID-19 Challenges
- Keywords
- COVID-19 vaccines, vaccine equity, global vaccine access, vaccine distribution, viral variants
- MeSH terms
- COVID-19, COVID-19 Vaccines, Humans, Global Health, Immunization Programs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
